Arcellx Inc (ACLX) AI Stock Analysis

• Market Cap: $5.20B
• Dividend Yield: N/A
• Average Volume (3M): 507.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: -76.96%
• EPS Growth: -425.41%
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.99
• Shares Outstanding: 57,822,872
• 10 Day Avg. Volume: 478,241
• 30 Day Avg. Volume: 507,732
• PEG Ratio: -1.06
• Price to Book (P/B): 9.03
• Price to Sales (P/S): 38.06
• P/FCF Ratio: -42.39
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 118.01
• Enterprise Value/Gross Profit: 5.23K
• Enterprise Value/Ebitda: -20.22
• 1Y Price Target: $114.73
• Price Target Upside: 27.51% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): -4.02
• Revenue Forecast (FY): $41.07M

• Rating: 52 Neutral
• Price Target: $91.00 ▲(1.13% Upside)

Arcellx Inc's overall stock score is primarily impacted by its poor financial performance, with significant losses and declining revenues. The technical analysis provides some positive momentum, but the valuation remains weak due to the negative P/E ratio. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Strategic Partnerships

Strategic partnerships provide funding for R&D and access to broader distribution networks, enhancing product reach and innovation potential.

Cash Flow Management

Positive cash flow growth, despite being from reduced negative cash flow, indicates improving efficiency in cash management, crucial for sustainability.

Low Leverage

Low leverage provides financial stability and flexibility, allowing the company to invest in growth opportunities without excessive debt burden.

Negative Factors

Declining Revenue

Declining revenue indicates challenges in market demand or competitive positioning, impacting long-term growth and profitability prospects.

Negative Profit Margins

Significant negative profit margins highlight operational inefficiencies and the need for cost management to achieve sustainable profitability.

Negative Operating Cash Flow

Negative operating cash flow indicates insufficient cash generation from core operations, posing risks to financial health and operational sustainability.

Arcellx Inc Business Overview & Revenue Model

Company Description

Arcellx Inc (ACLX) is a biotechnology company focused on developing innovative therapies for patients with cancer and other severe diseases. The company specializes in the development of its proprietary cell therapy platform, which leverages the unique properties of genetically engineered T cells to target and eliminate cancer cells. Arcellx is primarily engaged in the research, development, and commercialization of its lead product candidates, which are designed to address significant unmet medical needs in hematologic malignancies and other related conditions.

How the Company Makes Money

Arcellx generates revenue primarily through the development and commercialization of its therapeutic products. The company may earn revenue from product sales once its therapies receive regulatory approval and are launched in the market. Additionally, Arcellx can benefit from strategic partnerships and collaborations with larger pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on sales. These partnerships not only provide funding for ongoing research and development but also facilitate access to broader distribution networks and resources. Furthermore, grants and funding from governmental or non-profit organizations focused on cancer research may also contribute to the company's financial resources.

Arcellx Inc Financial Statement Overview

Summary

Arcellx Inc faces significant financial challenges, particularly in terms of profitability and cash flow. The company is struggling with declining revenues and persistent losses, which are impacting its financial health. While leverage is low, the negative return on equity and cash flow issues highlight the need for strategic improvements to achieve financial stability and growth.

Income Statement

Arcellx Inc's income statement reveals significant challenges. The company has experienced a substantial decline in revenue growth, with a negative growth rate of -25.82% in the TTM period. Profitability metrics are concerning, with negative net profit, EBIT, and EBITDA margins, indicating ongoing losses. The gross profit margin remains high, but this is overshadowed by the company's inability to achieve positive net income.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio of 0.13, suggesting manageable leverage. However, the return on equity is negative, indicating that the company is not generating returns for shareholders. The equity ratio is not explicitly calculated, but the company's equity position appears stable relative to its assets.

Cash Flow

Cash flow analysis highlights significant issues with negative operating cash flow and free cash flow. The free cash flow growth rate is positive in the TTM period, but this follows a period of negative growth. The operating cash flow to net income ratio is negative, reflecting cash flow challenges, although the free cash flow to net income ratio is slightly above 1, indicating some ability to cover net losses with free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	35.90M	107.94M	110.32M	0.00	0.00	0.00
Gross Profit	810.00K	102.75M	110.32M	-2.22M	0.00	0.00
EBITDA	-209.52M	-99.06M	-64.14M	-184.74M	-63.92M	-31.47M
Net Income	-217.90M	-107.35M	-70.69M	-188.68M	-64.97M	-32.09M
Balance Sheet
Total Assets	655.92M	711.33M	825.13M	313.82M	128.78M	57.69M
Cash, Cash Equivalents and Short-Term Investments	461.38M	587.58M	702.02M	254.84M	104.62M	46.60M
Total Debt	51.79M	54.08M	97.63M	88.13M	0.00	0.00
Total Liabilities	215.14M	256.54M	339.75M	108.86M	250.30M	7.15M
Stockholders Equity	440.78M	454.79M	485.38M	204.95M	-121.52M	50.54M
Cash Flow
Free Cash Flow	-201.18M	-96.90M	186.15M	-101.58M	-60.02M	-29.55M
Operating Cash Flow	-198.11M	-83.47M	207.57M	-99.30M	-54.24M	-28.66M
Investing Cash Flow	24.38M	-183.04M	-154.51M	-117.67M	-79.98M	-888.00K
Financing Cash Flow	90.88M	-24.09M	279.16M	252.63M	118.45M	41.66M

Arcellx Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 89.98
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACLX, the sentiment is Positive. The current price of 89.98 is above the 20-day moving average (MA) of 87.13, above the 50-day MA of 83.57, and above the 200-day MA of 70.47, indicating a bullish trend. The MACD of 1.44 indicates Positive momentum. The RSI at 57.42 is Neutral, neither overbought nor oversold. The STOCH value of 64.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACLX.

Arcellx Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PTGX	70 Neutral	$5.29B	133.58	7.80%	―	-35.39%	-72.97%
ACLX	52 Neutral	$5.20B	―	-47.18%	―	-76.96%	-425.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
APLS	51 Neutral	$2.53B	66.72	14.10%	―	42.11%	―
IMVT	45 Neutral	$4.16B	―	-95.93%	―	―	-27.70%
MLTX	41 Neutral	$911.44M	―	-54.17%	―	―	-157.74%
BEAM	40 Neutral	$2.20B	-4.90	-47.19%	―	-84.07%	-157.71%

Arcellx Inc Corporate Events

Arcellx, Inc. Reports Increased Loss Amid Rising Expenses

Arcellx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for cancer and other incurable diseases, operating within the biotechnology sector. In its latest earnings report for the quarter ending September 30, 2025, Arcellx reported a net loss of $55.8 million, reflecting increased operating expenses and a decline in collaboration revenue compared to the previous year. The company’s collaboration revenue from its partnership with Kite Pharma, a Gilead company, decreased significantly to $4.9 million for the quarter, down from $26 million in the same period last year. This decline was primarily due to changes in the timing of revenue recognition under the collaboration agreement. Despite the financial loss, Arcellx continues to advance its pipeline, with significant investments in research and development, particularly in its lead product candidate, anito-cel, for the treatment of multiple myeloma. Looking ahead, Arcellx remains focused on its strategic collaborations and the development of its innovative therapies, with management expressing confidence in its cash reserves to fund operations into 2028.

Arcellx’s iMMagine-3 Study: A Potential Game-Changer for Multiple Myeloma Treatment

Study Overview: The iMMagine-3 study aims to evaluate the efficacy and safety of anitocabtagene autoleucel compared to standard of care therapy (SOCT) in patients with relapsed/refractory multiple myeloma (RRMM) who have undergone 1 to 3 prior treatments, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. This Phase 3 trial is significant as it seeks to provide an alternative treatment option for RRMM, potentially improving patient outcomes.

Arcellx Advances in Autoimmune Treatment with Anitocabtagene Autoleucel Study

Study Overview: Arcellx, Inc. is conducting a Phase 1 clinical study titled ‘A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases’. The study aims to evaluate the safety, tolerability, and preliminary efficacy of anito-cel, a BCMA-directed CAR-T cell therapy, in patients with generalized myasthenia gravis (GMG). This research is significant as it explores a novel treatment approach for autoimmune diseases affecting the nervous system.